drugset / Trial / NCT03675880

TAB014(Drug Code) in Wet( Neovascular)Age-related Macular Degeneration(AMD) Subjects

NCT03675880

Phase 1 Unknown 24 enrolled Lee's Pharmaceutical Limited
RandomizedParallel-groupOpen-labelTreatment

Summary

Subjects with secondary wet age-related macular degeneration(AMD) or recurrent subfoveal choroidal neovascularization (CNV) in only one study eye will be enrolled into the study.

Timeline

Start
2018-06-15
Primary completion
2019-02-15
Completion
2019-04-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject TAB014 Monoclonal antibody 1.25 mg Intravitreal
Subject TAB014 Monoclonal antibody 2 mg Intravitreal
Subject TAB014 Monoclonal antibody 2.5 mg Intravitreal

Indications

No indication recorded.